A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis

A sixth month phase II multicenter-pilot trial with a low dose of the opiate antagonist Naltrexone (LDN) has been carried out in 40 patients with primary progressive multiple sclerosis (PPMS). The primary end points were safety and tolerability. Secondary outcomes were efficacy on spasticity, pain,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis 2008-09, Vol.14 (8), p.1076-1083
Hauptverfasser:	Gironi, M, Martinelli-Boneschi, F, Sacerdote, P, Solaro, C, Zaffaroni, M, Cavarretta, R, Moiola, L, Bucello, S, Radaelli, M, Pilato, V, Rodegher, ME, Cursi, M, Franchi, S, Martinelli, V, Nemni, R, Comi, G, Martino, G
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Depression - epidemiology Disabled Persons Fatigue - epidemiology Female Humans Male Medical sciences Middle Aged Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Chronic Progressive - genetics Multiple Sclerosis, Chronic Progressive - physiopathology Naltrexone - therapeutic use Neurology Pilot Projects Polymorphism, Single Nucleotide Receptors, Opioid, mu - genetics RNA, Messenger - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!